# **PMA** Checklist



As you plan for a PMA Application Submission, check out the table below for a summary of the FDA's PMA acceptance and filing checklist.

Note: Throughout the document, the term "product" refers to a digital health product that entails either a medical device and/or a combination product unless indicated otherwise for specific reasons.

### **Checklist for Acceptance Review for PMAs**

#	Information		Yes	No	N/A
Pre	liminary questions				
1		ice or a combination product (device + constituent part subject to review under			
2	If the product is a device or a combination product with a device constituent part, is it subject to review by the Center in which the application was received?				
3	Has a Request for Designation (RFD) been submitted? If so:	Does the product have the same design/formulation as that presented in the RFD submission?			
	If no, mark N/A  Note: RFD isn't required. FDA reviews use this process to ensure the application is filed with the relevant FDA review division.	Are the products and indications for use the same in the PMA and RFD submission?			
4	If the product is a combination product, is the drug component currently approved with exclusivity? If "Yes," then contact the CDRH Product Jurisdiction Officer or CBER Product Jurisdiction Officer, provide a summary of the discussion with them, and indicate their recommendation/action.  Choose "N/A" if the product is not a combination product.				
5	Is Class III/PMA revie	ew required for the device?			
6	Is there a pending 5° the same indications	10(k) submission for the same device with s for use?			

7	Is the manufacturer currently on the FDA's <u>Application Integrity Policy (AIP) list</u> ?							
Org	Organizational and Administrative Elements							
1	accompanied with a	ions of the application in English or n English translation (includes written or terature, articles, etc.)?						
2	Is there a table of contents?							
3	Is a bibliography pro	vided?						
4	If a device sample has been requested by the FDA, has it been provided, or, if impractical to submit, has the applicant offered alternatives to allow FDA staff to view or access the device?							
5	Is there a summary	of the contents of the PMA?						
6	Is the description of the product included?	Does the description include pictorial representations and material specifications?						
	If no, mark N/A.	Does the provided description include the principles of operation of the device (including components) and properties relevant to clinical function?						
7	Is the Device Manufacturing Section included and does it contain a description of the methods, facilities, and controls used in the manufacture, processing, packing, storage, and installation of the device?							
8	Are summaries of	a. Sterilization						
	the nonclinical laboratory studies and full test	b. Biological/Microbiological						
	reports provided? Including, as	c. Immunological						
	applicable:	d. Toxicological/Biocompatibility						
	If no, mark N/A.	e. Engineering (stress, wear, etc.)						
		f. Chemistry/Analytical (typically for In-Vitro Diagnostics)						
		g. Shelf Life						
		h. Animal Studies						

		i. Other Essential Laboratory Testing		
9	Is a summary of the clinical	Are the final versions of the clinical protocols included?		
	investigation(s) and results provided?	Is a description of study population demographics provided?		
	If no, mark N/A.	Is a description of adverse events (e.g., adverse reactions, complaints, discontinuations, failures, replacements) given?		
		Have report forms for patients who died or who did not complete the investigation been provided (i.e., to resolve potential bias)?		
10	Are statistical analystheir results, provide	ses of the clinical investigations, as well as ed?		
11	Has appropriate	Physician Labeling		
	draft physician and patient labeling	1. Are indications for use included?		
	been submitted?	<ol><li>Are contraindications, warnings, and precautions included?</li></ol>		
	If no, mark N/A.	3. Are instructions for use included?		
		Patient Labeling		
		(Check "N/A" if FDA indicated that patient labeling is not necessary.)		
		Technical/operator's manual		
Sta	tements/Certificatior	ns/Declarations of Conformity		
1	Does the application utilize voluntary consensus standard(s)?  If no, mark N/A.	If yes, does the application include: a Declaration of Conformity (DOC) as outlined in the FDA's guidance document, "Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices,"  or  If citing general use of a standard, the basis of such use is included along with the underlying information or data that supports how the standard was used?		

		If the application cites non-FDA-recognized voluntary consensus standard(s), does the application include the basis of use along with the underlying information or data that supports how the standard was used?		
2	Investigator Financial Disclosure	Has the applicant provided documentation to establish that they have followed the recommendations in applicable FDA guidance/guidelines or otherwise met applicable statutory or regulatory criteria?		
		Has the applicant submitted either a signed and dated Certification Form (3454) or a signed and dated Disclosure Form (3455)?		
		For a Certification Form (3454): Is the required list of all investigators and subinvestigators attached to the Form, or does the Form include the reason(s) why financial disclosure information could not be obtained?		
		For a Disclosure Form (3455): Does the application provide details of the financial arrangements and interests of the investigator(s) or subinvestigator(s), along with a description of any steps taken to minimize potential bias?		
3	devices that present	assessment included (ONLY required for new environmental concerns)? Or, if all exclusion, does the application include y the exclusion?		
4	FDA Form 3674	Did the application include a completed FDA form 3674, Certification with Requirements of ClinicalTrials.gov Data Bank?		
		Does the form indicate if:  1. There are no clinical trials referenced in submission?  or  2. Requirements are not applicable to		

		referenced clinical trials?  or  3. Requirements are applicable and have been met?		
5	For all clinical investigations	1. A statement of compliance with 21 CFR parts 50, 56, and 812, OR		
	conducted in the U.S., does the application include one of the following for each investigation:	<ol> <li>A brief statement of the reason for noncompliance with 21 CFR parts 50, 56, and 812?</li> </ol>		
investiga conduct of the U the appl includes the follo	For all clinical investigations conducted outside of the U.S., does the application includes one of	1. A statement that the clinical investigations were conducted in accordance with good clinical practice (GCP) as described in 21 CFR 812.28(a)(1), OR		
	the following for each investigation:	2. A brief statement of the reason for not conducting the investigation in accordance with GCP and a description of steps taken to ensure that the data and results are credible and accurate and that the rights, safety, and well-being of subjects have been adequately protected, OR		
		3. A waiver request in accordance with 21 CFR 812.28(c)?		
Ped	iatric Use Provisions			
1	subpopulations that	include a description of any pediatric suffer from the disease or condition that ed to treat, diagnose, or cure,		
	or			
	disease or condition	pediatric subpopulation exists for the for which the device is intended, as well diatric patients affected?		
	NOTE: This statement treating pediatric patie	does not mean the device is indicated for ents.		

Combination Product Provisions						
1	If your product is a combination	Does the application identify it as such?				
	product:	Does the application include an appropriate patent statement or certification and a statement that the applicant will give notice, as applicable?				
2	Does the request describe how the device is relevant to the diagnosis, treatment, prevention, cure, or mitigation of a disease or condition?					
3	Does the request provide a complete description of all the functional parts or components of the product? (This description should include any parts or accessories that are marketed with the device.)					
4	If the product will be marketed with other devices (such as parts or accessories) that have already been approved by the FDA, does the request include a list of relevant FDA-assigned reference number(s)?					
Hist	tory of the Applicatio	1				
1	1	Does the applicant list prior submissions or state that there were no prior submissions? If so, which of these are	1. 510(k)  If this device has been the subject of an not substantially equivalent (NSE) decision, does the pre-market approval (PMA) address any issues relating to safety or effectiveness?			
	included?	2. IDE (Investigational Device Exemption)  Have the data presented in the PMA taken into account any safety or effectiveness concerns (e.g. "future considerations") previously communicated through IDE correspondence?				
		3. <b>Prior PMA</b> (includes Modular PMA)  If a previously submitted PMA for this device has been withdrawn, does the current PMA address any issues related to safety or effectiveness raised during review of the prior PMA?				

<ol> <li>If a modular PMA was submitted, has the number of modules in the following categories been included in the application, as applicable?  If no, mark N/A.</li> <li>Further, If there are modules that are on hold, does the address outstanding deficiencies?</li> </ol>			
following categories been included in the application, as applicable?  If no, mark N/A.  3 Further, If there are modules that are on hold, does the address outstanding deficiencies?	dules		
application, as applicable?  If no, mark N/A.  3. Does it have number of mode hold hold  Surther, If there are modules that are on hold, does the address outstanding deficiencies?	dules		
address outstanding deficiencies?	dules on		
A Despths amplicant If anyther the O. O. I	ne PMA		
<ul> <li>Does the applicant lists Q-Submissions, application include, as applicable Q-Submission(s) regarding the</li> <li>Q-Submission #,</li> </ul>			
device or this application in Meeting date(s),			
which FDA Copy of minutes from each feedback regarding data or Copy of minutes from each meeting or other written from the copy of minutes from each meeting or other written from the copy of minutes from each meeting or other written from the copy of minutes from each meeting or other written from the copy of minutes fr			
information related to safety and/or effectiveness in the PMA was provided by email or during a meeting (in person or by phone), or state that there were no prior Q-Submission interactions with the FDA regarding this application?  Were all staff concerns or action previously presented to the application addressed in the PMA,  or  has the applicant provided a det scientific or clinical justification alternative approach?  If no, mark N/A.	icant in edback cailed		

# **Checklist for Filing Review for PMAs**

#		Information	Yes	No	N/A
Тес					
1	1. The protocol or the spons	stent with the following, as applicable: in the approved IDE (if one was required) or's study protocol for a foreign study (i.e., olely outside of the U.S.);			
	2. Recommend and/or	ations from a Q-Submission interaction;			
	3. A device spe	cific guidance document?			
2	Does the application include a	<ol> <li>Sample size/number of patients enrolled and completing the study?</li> </ol>			
	description of the following elements:  If no, mark N/A.	2. Follow-up duration for the primary analysis?			
		3. Follow-up evaluations for the primary analysis?			
		4. Study Objectives?			
		5. Study Population/Enrollment Criteria?			
		6. Study Endpoints?			
		7. Study Design?			
		8. Hypothesis?			
		9. Statistical Analysis?			
3	Does the patient/st	udy population match the intended use?			
4	Have clinically signi	ficant endpoints been selected?			
5	application include	v is based on foreign clinical data, does the a justification with respect to how the data be U.S. patient population?			

#### **Pre-Market Approval (PMA)**



#### DiMe Resources











Access DiMe's Digital Health Regulatory Pathway Resources







**Interact** with regulators